Apimeds Pharmaceuticals US, Inc.
APUS · XNYSCIK 1894525fmd_0MBV36M13SRZ5XXWYT9HC2FMG5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Jun 30, 2026, 11 periods
Latest annual · FY2025
Millions- Operating income
- (12)
- Net income
- (6)
- Free cash flow
- (9)
Latest quarter · Q2 FY2026
Millions- Operating income
- (6)
- Net income
- (20)
- Free cash flow
- (6)
Daily close · APUSIEX trades only
Nov 11, 2026 to Nov 11, 2026 · 1 sessions2.28 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Apimeds Pharmaceuticals US, Inc. (APUS) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$11.9 million | -$1.3 million | 10-K 2026-05-04 · proof | |
| Net income | -$6 million | -$1.4 million | 10-K 2026-05-04 · proof | |
| Cash from operating activities | -$8.9 million | -$733,526 | 10-K 2026-05-04 · proof | |
| Free cash flow | -$9 million | 10-K 2026-05-04 · proof | ||
| Total assets | $164.2 million | $13,057 | +1,257,338.4% | 10-K 2026-05-04 · proof |
| Total liabilities | $10.8 million | $1.4 million | +690.3% | 10-K 2026-05-04 · proof |
| Cash and cash equivalents | $1.6 million | $3,455 | +47,270.6% | 10-K 2026-05-04 · proof |
- What was Apimeds Pharmaceuticals US, Inc. (APUS)'s operating income in fiscal 2025?
- Apimeds Pharmaceuticals US, Inc. (APUS) reported operating income of -$11.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$1.3 million the year before. Source: the 10-K filed with the SEC on May 4, 2026. SEC
- What was Apimeds Pharmaceuticals US, Inc. (APUS)'s net income in fiscal 2025?
- Apimeds Pharmaceuticals US, Inc. (APUS) reported net income of -$6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$1.4 million the year before. Source: the 10-K filed with the SEC on May 4, 2026. SEC
- What was Apimeds Pharmaceuticals US, Inc. (APUS)'s cash from operating activities in fiscal 2025?
- Apimeds Pharmaceuticals US, Inc. (APUS) reported cash from operating activities of -$8.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$733,526 the year before. Source: the 10-K filed with the SEC on May 4, 2026. SEC
- What was Apimeds Pharmaceuticals US, Inc. (APUS)'s free cash flow in fiscal 2025?
- Apimeds Pharmaceuticals US, Inc. (APUS) reported free cash flow of -$9 million for fiscal 2025 (the year ended Dec 31, 2025). Source: the 10-K filed with the SEC on May 4, 2026. SEC
- What are Apimeds Pharmaceuticals US, Inc. (APUS)'s total assets?
- As of Dec 31, 2025, Apimeds Pharmaceuticals US, Inc. (APUS) reported total assets of $164.2 million, against $13,057 a year earlier (+1,257,338.4%). Source: the 10-K filed with the SEC on May 4, 2026. SEC
- What are Apimeds Pharmaceuticals US, Inc. (APUS)'s total liabilities?
- As of Dec 31, 2025, Apimeds Pharmaceuticals US, Inc. (APUS) reported total liabilities of $10.8 million, against $1.4 million a year earlier (+690.3%). Source: the 10-K filed with the SEC on May 4, 2026. SEC
- What are Apimeds Pharmaceuticals US, Inc. (APUS)'s cash and cash equivalents?
- As of Dec 31, 2025, Apimeds Pharmaceuticals US, Inc. (APUS) reported cash and cash equivalents of $1.6 million, against $3,455 a year earlier (+47,270.6%). Source: the 10-K filed with the SEC on May 4, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:APUS&period_type=annual&limit=5"Information only, not investment advice.